Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

MAIA Biotechnology, Inc. Common Stock (NY:MAIA)

1.660 UNCHANGED

Streaming Delayed Price Updated: 8:00 PM EST, Jan 8, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	9,018
Open	1.660
Bid (Size)	1.630 (200)
Ask (Size)	1.660 (200)
Prev. Close	1.660
Today's Range	1.660 - 1.660
52wk Range	0.8700 - 2.740
Shares Outstanding	37,032,307
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Which stocks are gapping on Monday? ↗

December 01, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

Biotech Giant MAIA Biotechnology (NYSE American: MAIA) Dives Headfirst into Crypto with Audacious Treasury Strategy

October 07, 2025

October 7, 2025 – In a move that sent ripples across both the biotechnology and cryptocurrency sectors, MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company...

Via BreakingCrypto

Performance

YTD	+3.7%	+3.7%
1 Month	+23.0%	+23.0%
3 Month	-3.5%	-3.5%
6 Month	-14.0%	-14.0%
1 Year	-22.1%	-22.1%

More News

Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion

October 06, 2025

Via FinancialNewsMedia

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 02, 2025

Via Benzinga

MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer

July 28, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy

July 17, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

July 09, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress

July 01, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

June 24, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars ↗

June 18, 2025

Via Stocktwits

MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

June 18, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology to Present at BIO International Convention 2025

June 10, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients ↗

June 05, 2025

Via Benzinga

MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial

June 05, 2025

From MAIA Biotechnology

Via Business Wire

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer

June 05, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000

May 27, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 15, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces Director Participation in Recent Private Placement

May 14, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement

May 05, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces $1.08 Million Private Placement

May 05, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

April 01, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

March 25, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

March 20, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO

March 19, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

February 27, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

Frequently Asked Questions

Is MAIA Biotechnology, Inc. Common Stock publicly traded?

Yes, MAIA Biotechnology, Inc. Common Stock is publicly traded.

What exchange does MAIA Biotechnology, Inc. Common Stock trade on?

MAIA Biotechnology, Inc. Common Stock trades on the New York Stock Exchange

What is the ticker symbol for MAIA Biotechnology, Inc. Common Stock?

The ticker symbol for MAIA Biotechnology, Inc. Common Stock is MAIA on the New York Stock Exchange

What is the current price of MAIA Biotechnology, Inc. Common Stock?

The current price of MAIA Biotechnology, Inc. Common Stock is 1.660

When was MAIA Biotechnology, Inc. Common Stock last traded?

The last trade of MAIA Biotechnology, Inc. Common Stock was at 01/08/26 08:00 PM ET

What is the market capitalization of MAIA Biotechnology, Inc. Common Stock?

The market capitalization of MAIA Biotechnology, Inc. Common Stock is 61.47M

How many shares of MAIA Biotechnology, Inc. Common Stock are outstanding?

MAIA Biotechnology, Inc. Common Stock has 61M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.